DeepMed Research

BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

A Study to Learn More About What Japanese Patients With Solid Tumors Think About Taking Medicine That is Based on Their Genetic Information

Completed

Conditions: Cancer Genomic Profiling

Interventions: Other: Survey

First Posted Date: 2020-10-29

Last Posted Date: 2022-10-13

Lead Sponsor: Bayer

Target Recruit Count: 605

Registration Number: NCT04607889

Locations: 🇯🇵
Many locations, Multiple Locations, Japan

A Study to Learn More About the Safety of Ultravist in Children and in the Elderly

Completed

Conditions: Hypersensitivity

Interventions: Drug: Iopromide(Ultravist, BAY86-4877)

First Posted Date: 2020-10-28

Last Posted Date: 2021-07-20

Lead Sponsor: Bayer

Target Recruit Count: 132850

Registration Number: NCT04605471

Locations: 🇩🇪
Four company sponsored non-interventional studies with iopromide, Berlin, Germany

Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

Phase 4

Active, not recruiting

Conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
Drug: NAH therapy

First Posted Date: 2020-10-22

Last Posted Date: 2025-05-20

Lead Sponsor: Bayer

Target Recruit Count: 696

Registration Number: NCT04597125

Locations: 🇫🇷
Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-les-Nancy, France
🇫🇷
Gustave Roussy - Departement Oncologie-Radiotherapie, Villejuif Cedex, France
🇦🇺
Specialist Services Medical Group, Castle Hill, New South Wales, Australia

and more 115 locations

A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before

Completed

Conditions: Bone Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: Radium 223 dichloride (Xofigo, BAY88-8223)

First Posted Date: 2020-10-14

Last Posted Date: 2024-03-08

Lead Sponsor: Bayer

Target Recruit Count: 1067

Registration Number: NCT04587427

Locations: 🇳🇱
Many Locations, Multiple Locations, Netherlands

A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A

Phase 4

Completed

Conditions: Hemophilia A

Interventions: Biological: Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2
Biological: Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1
Biological: Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3

First Posted Date: 2020-09-25

Last Posted Date: 2025-04-18

Lead Sponsor: Bayer

Target Recruit Count: 45

Registration Number: NCT04565236

Locations: 🇨🇳
The Children's Hospital Zhejiang University School of Med, Hangzhou, Hangzhou Province, China
🇨🇳
Beijing Children's Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
Shijiazhuang General Hospital, Shijiazhuang, Hebei, China

and more 7 locations

Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough

Phase 2

Completed

Conditions: Refractory and/or Unexplained Chronic Cough

Interventions: Drug: Placebo
Drug: BAY1817080

First Posted Date: 2020-09-24

Last Posted Date: 2022-08-18

Lead Sponsor: Bayer

Target Recruit Count: 310

Registration Number: NCT04562155

Locations: 🇧🇪
VZW Emmaus, Mechelen, Belgium
🇭🇺
Da Vinci Maganklinika, Pecs, Hungary
🇭🇺
Farmakontroll Bt., Szazhalombatta, Hungary

and more 96 locations

Study to Learn More About the Effect of a New Drug Called BAY2327949 on the Blood Flow Through Kidneys in Adult Participants With Moderate Chronic Kidney Disease

Phase 1

Terminated

Conditions: Moderate Chronic Kidney Disease

Interventions: Drug: BAY2327949
Drug: Placebo

First Posted Date: 2020-09-17

Last Posted Date: 2022-08-23

Lead Sponsor: Bayer

Target Recruit Count: 7

Registration Number: NCT04552262

Locations: 🇩🇰
Steno Diabetes Center Copenhagen, Herlev, Denmark

Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB)

Phase 2

Completed

Conditions: Overactive Bladder

Interventions: Drug: Placebo
Drug: BAY1817080

First Posted Date: 2020-09-11

Last Posted Date: 2022-12-22

Lead Sponsor: Bayer

Target Recruit Count: 99

Registration Number: NCT04545580

Locations: 🇦🇹
Medizinische Universität Graz, Graz, Steiermark, Austria
🇵🇹
Centro Hospitalar Universitario do Porto, Porto, Portugal
🇦🇺
Emeritus Research, Camberwell, Victoria, Australia

and more 24 locations

Study to Find Out Whether Participants With a History of Stuffy Nose Due to Allergic Reactions in the Nose Would Intend to Buy Drug Phenylephrine Hydrochloride Extended Release Tablets After Receiving it Once in This Study

Phase 3

Completed

Conditions: Nasal Congestion Due to Allergic Rhinitis

Interventions: Drug: Phenylephrine HCl (Sinus Comfort, BAY112476)

First Posted Date: 2020-09-01

Last Posted Date: 2020-09-01

Lead Sponsor: Bayer

Target Recruit Count: 347

Registration Number: NCT04534452

Locations: 🇺🇸
Allergy & Asthma Specialists, PC, Blue Bell, Pennsylvania, United States

Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.

Phase 3

Completed

Conditions: Overactive Bladder

Interventions: Drug: Oxybutynin (Oxytrol, BAY839380)

First Posted Date: 2020-09-01

Last Posted Date: 2020-10-20

Lead Sponsor: Bayer

Target Recruit Count: 855

Registration Number: NCT04534491

Locations: 🇺🇸
Stevenson Family Pharmacy, Saint Joseph, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy